medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2012, Number 602

<< Back Next >>

Rev Med Cos Cen 2012; 69 (602)

Artritis reumatoide

Acón RD, Zapata AN, Méndez RA

Language: Spanish
References: 16
Page: 299-307
PDF size: 181.70 Kb.


ABSTRACT

Rheumatoid arthritis is a chronic, autoimmune, inflammatory and systemic disease, which mainly affects synovial tissues. Without and early diagnosis and appropriate treatment, occurs disability joint deformity and early death in these patients.
Over the past two decade, the treatment of RA has been revolutionized by advances in the understanding of its pathologic mechanisms, being these mechanisms the targets of the development of new therapies, increasing therapeutic options for these patients.


REFERENCES

  1. Aletaha D, Neogi T, Silman A. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-1588.

  2. Edwards J, Szczepanski L, Szechinski J et cols. Efficacy of B- cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng J Med 2004; 350; 2572-2581

  3. Emery P, Keystone E, Tony H et cols. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in pacientes rheumatoid arthritis refractory to anti-TNF biologics: results from a 24- week multicentre randomized placebo controlled trial. Ann Rheum Dis 2008

  4. Finckh A, Bansback N, Marra C et cols. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs or biologic agents. Ann Inter Med 2009; 151: 612-621

  5. Fox D, Gizinski A, Morgan R, Lundy S. Cell-cell interactions in Rheumatoid Arthritis Synovium. Rheum Dis Clin N Am 2010; 36: 311-323

  6. Genovese M, Becker J, Schiff M et cols. Abatacept for rheumatoid arthritis refractory to tumor necrosis ƒ¿ inhibition. N Eng J Med 2005; 353: 1114-1123

  7. Kahlenberg J, Fox D. Advances in the medical treatment of Rheumatoid Arthritis. Hand Clin 2011; 27: 11-20

  8. Nishimura N, Sugiyama D, Kogata Y et cols. Meta-analysis: Diagnostic accuracy of anti- cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808

  9. OLDell J. Therapeutic strategies for rheumatoid arthritis. N Eng J Med 2004; 350: 2591-2602

  10. Olsen N, Stein M. New drugs for rheumatoid arthritis. N Eng J Med 2004; 350: 2167-2179

  11. Rubbert A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Research and Therapy 2009

  12. Smith J, Haynes M. Rheumatoid Arthritis- A molecular understanding. Ann Intern Med 2002; 136: 908-922

  13. Van Everdigen A, Jacobs J, Siewertsz D. Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties and side effects. Ann Intern Med 2002; 136: 1-12

  14. Weinblatt M, Kavanaugh A, Genovese M et col. An oral spleen tyrosine kynase inhibitor for rheumatoid arthritis. N Eng J Med 2010; 363: 1303-1312

  15. Whiting P, Smidt N, Stern J et cols. Systematic review: accuracy of anticitrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152: 456-464

  16. Wong M, Jiang B, Mcneill K et cols. Effects of selective and non selective cyclo-oxygenase inhibition of endothelial function of patients with rheumatoid arthritis. Scand J Rheumatology 2007; 36: 265-269




2020     |     www.medigraphic.com